Erasca (ERAS) Operating Leases (2020 - 2026)
Erasca (ERAS) reported Operating Leases of $40.7 million for Q1 2026, down 11.56% on a YoY basis from $46.0 million in Q1 2025, and down 3.26% quarter-over-quarter from $42.1 million in Q4 2025.
Erasca (ERAS) Operating Leases (2020 - 2026) Analysis & Trends
Erasca has reported Operating Leases for 7 years, with the latest figure at $40.7 million in Q1 2026.
- For the quarter ending Q1 2026, Operating Leases fell 11.56% year-over-year to $40.7 million; the trailing twelve-month figure through Mar 2026 stood at $40.7 million (down 11.56% YoY), and the FY2025 full-year result was $42.1 million, down 10.99% from the prior year.
- Operating Leases for Q1 2026 stood at $40.7 million, down from $42.1 million in the prior quarter.
- The five-year high for Operating Leases was $54.9 million in Q1 2023, with the low at $27.4 million in Q2 2022.
- Historically, Operating Leases has averaged $46.5 million across 5 years, with a median of $48.5 million in 2024.
- Annual changes were most pronounced in 2022 — Operating Leases jumped 1544.9% — and 2026, when it declined 11.56%.
- Erasca's Operating Leases stood at $53.8 million in 2022, then retreated by 3.54% to $51.9 million in 2023, then decreased by 8.9% to $47.3 million in 2024, then declined by 10.99% to $42.1 million in 2025, then dropped by 3.26% to $40.7 million in 2026.
- The last three Operating Leases figures came in at $40.7 million (Q1 2026), $42.1 million (Q4 2025), and $43.4 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Erasca | 4.16 Bn | 3.92 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 40.70 Mn |
| Dec 31, 2025 | 42.07 Mn |
| Sep 30, 2025 | 43.41 Mn |
| Jun 30, 2025 | 44.71 Mn |
| Mar 31, 2025 | 46.02 Mn |
| Dec 31, 2024 | 47.27 Mn |
| Sep 30, 2024 | 48.49 Mn |
| Jun 30, 2024 | 49.68 Mn |
| Mar 31, 2024 | 50.81 Mn |
| Dec 31, 2023 | 51.89 Mn |
| Sep 30, 2023 | 52.94 Mn |
| Jun 30, 2023 | 53.97 Mn |
| Mar 31, 2023 | 54.94 Mn |
| Dec 31, 2022 | 53.79 Mn |
| Sep 30, 2022 | 53.43 Mn |
| Jun 30, 2022 | 27.44 Mn |
| Mar 31, 2022 | 29.42 Mn |
| Dec 31, 2021 | 18.51 Mn |
| Sep 30, 2021 | 19.37 Mn |
| Jun 30, 2021 | 1.67 Mn |